Skip to main content
Alanna Morris, MD, Cardiology, Gainesville, GA

Alanna A Morris MD

Adult Congenital Heart Disease, Heart Failure & Transplantation


Physician

Join to View Full Profile
  • 743 Spring St NEGainesville, GA 30501

  • Phone+1 770-534-2020

  • Fax+1 404-778-5650

Are you Dr. Morris?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Alanna Morris, MD is a cardiologist in Gainesville, Georgia. She is currently licensed to practice medicine in Georgia and Massachusetts.

Education & Training

  • Emory University School of Medicine
    Emory University School of MedicineFellowship, Cardiovascular Disease, 2008 - 2012
  • Mass General Brigham/Brigham and Women's Hospital
    Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2005 - 2008
  • Harvard Medical School
    Harvard Medical SchoolClass of 2005

Certifications & Licensure

  • GA State Medical License
    GA State Medical License 2008 - 2025
  • MA State Medical License
    MA State Medical License 2007 - 2009
  • Advanced Heart Failure and Transplant Cardiology
    American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology
  • Cardiovascular Disease
    American Board of Internal Medicine Cardiovascular Disease

Publications & Presentations

PubMed

Press Mentions

  • Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking New Indication for KERENDIA® (Finerenone) in Patients with Heart Failure with Left Ventricular Ejection Fraction of ≥40%
    Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking New Indication for KERENDIA® (Finerenone) in Patients with Heart Failure with Left Ventricular Ejection Fraction of ≥40%January 10th, 2025
  • Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking New Indication for KERENDIA® (Finerenone) in Patients with Heart Failure with Left Ventricular Ejection Fraction of ≥40%
    Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking New Indication for KERENDIA® (Finerenone) in Patients with Heart Failure with Left Ventricular Ejection Fraction of ≥40%January 10th, 2025
  • ACC/AHA Clarify How Social Determinants of Health Impact CVD
    ACC/AHA Clarify How Social Determinants of Health Impact CVDAugust 28th, 2024
  • Join now to see all